

BIBLIOGRAFÍA

CAPÍTULO I

1. *History drugs*: <http://itsa.ucsf.edu/~ddrc/histdrgr>
2. Escohotado, A., *Historia general de las drogas*, Espasa, 3a. ed., 2000.
3. www.erowid.org

CAPÍTULO II

1. Siegel, G., *Basic Neurochemistry: molecular, cellular and medical aspects*, 6a. ed. en CD-ROM, Lippincott-Raven, 1999.
2. Watkins, S., Koob, G. y Markou, A., “Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal”, *Nicotine & Tobacco Research*, 2:19:37, 2000.
3. Littleton, J., “Neurochemical mechanisms underlying alcohol withdrawal”, *Alcohol Health & Research World*, 22(1):13-24, 1998.
4. Himmelsbach, C. K., “The morphine abstinence syndrome, its nature and treatment”, *Annals of Internal Medicine*, 15:829-843, 1941.
5. Wise, R. A., “Animals models of addiction”, *Neurobiology of Mental Illness*, Oxford University Press, 1999.

CAPÍTULO III

1. Baxter, L. R., Schwartz, J. M., Phelps, M. E. y Mazziotta, J. C., “Localization of neurochemical effects of cocaine and other stimulants in the human brain”, *J Clin. Psychiatry*, 49:23-26, 1988.
2. Ding, Y. S., Gatley, S. J., Fowlers, J. S. y Volkow, N. D., “Mapping nicotinic acetylcholine receptors with PET”, *Synapse*, 24:403-407, 1996.
3. Fowlers, J. S., Volkow, N. D., Wang, G. J. y Pappas, N., “Brain

- monoamine oxidase. A inhibition in cigarette smokers”, *Proc. Natl. Acad. Sci*, 93:14065-14069, 1996.
4. Fowler, J. S., Volkow, N. D., Wolf, A. P. y Dewey, S. L., “Mapping cocaine binding in human and baboon brain in vivo”, *Synapse*, 4:371-377, 1989.
 5. Fowlers, J. S., Volkow, N. D., Wang, G. J. y Pappas, N., “Inhibition of MAO B in the brain of smokers”, *Nature*, 379:733-736, 1996.
 6. Fowlers, J. S. y Volkow, N. D., “PET imaging studies in drug abuse”, *Clin. Toxicology*, 36:163-174, 1998.
 7. Fowler, J. S., Volkow, N. D., Malison, R. y Gatley, J., “Neuroimaging studies of substance abuse disorders”, *Neurobiology of Mental Illness*, Oxford University Press, 1999.
 8. Volkow, N. D., Wang, G. J., Fowlers, J. S. y Gatley, S. J., “Relationship between psychostimulant induced high and dopamine transport occupancy”, *Proc. Natl. Acad. Sci*, 93:10388-10392, 1996.
 9. Volkow, N. D., Wang, G. J. y Doria, J. J., “Monitoring the brain’s response to alcohol with positron emission tomography”, *Alcohol Health Res World*, 19:196-209, 1996.

CAPÍTULO IV

1. Lancaster, T., “Silver acetate for smoking cessation”, *The Cochrane Library*, 1997.
2. Silagy, C., Mant, D., Fowler, G., “Nicotine replacement therapy for smoking cessation”, *The Cochrane Library*, 2000.
3. Stead, L. F., Hughes, J. R., “Lobeline for smoking cessation”, *The Cochrane Library*, 1997.
4. Gourlay, S. G., Stead, L. F., Benowitz, N. L., “Clonidine for smoking cessation”, *The Cochrane Library*, 1998.
5. World Health Organization, <http://www.tobacco.who.int>
6. Shine, B., “Nicotine vaccine moves toward clinical trial”, *NIDA notes*, 15(5):1, 2000.
7. Lukas, R. J., Changeux, J. P. *et al.*, “International union of pharmacology. xx. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits”, *Pharmacological Reviews*, 51(2):397-401, 1999.
8. Glassman, A. H., Stetner, F., Walsh, B. T., Raizman, P. S., Fleiss, J.

- L., Cooper, T. B. y Covey, L. S., "Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial", *JAMA*, 259:2863-2866, 1998.
9. Kaplan y Sadock's, *Comprehensive Textbook of Psychiatry*, 7a. ed. en CD-ROM, Lippincott Williams & Wilkins, 2000.
 10. Siegel, G., *Basic Neurochemistry: molecular, cellular and medical aspects*, 6a. ed. en CD-ROM, Lippincott-Raven, 1999.
 11. Goodman y Gilman's, *The pharmacological Basis of Therapeutics*. 9a. ed. en CD-ROM, McGraw-Hill, 1996.
 12. Schneider, R., "Update in addiction medicine", *Ann Intern Med*, 134:387-395, 2001.
 13. Slemmer, J., "Bupropion is a nicotinic antagonist", *The Journal of Pharmacology and Experimental Therapeutics*, 295(1):321-327, 2000.
 14. Watkins, S., Koob, G., Markou, A., "Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal", *Nicotine & Tobacco Research*, 2:19-37, 2000.
 15. Mihailescu, S., Drucker-Colin, R., "Nicotine and brain disorders", *Acta Pharmacol Sin*, 21(2):97-104, 2000.
 16. Levin, E. D., Rezvan, A. H., "Development of nicotinic drug therapy for cognitive disorders", *Eur J Pharmacol*, 393(1-3):141-146, 2000.
 17. Dale, L. C., Glover, E. D., Sachs, D. *et al.*, "Bupropion for smoking cessation. Predictors of successful outcome", *Chest*, 119:1357-1364, 2001.

CAPÍTULO V

1. Anton, R., "What is craving? Models and implications for treatment", *Alcohol Research & Health*, 23(3):165-173, 1999.
2. Besson, J., "New drugs in the treatment of alcoholism", *Schweiz Med Wochenschr*, 127(38):1574, 1997.
3. Chick, J., *Alcohol Alcohol*, 30(6):785-787, 1995.
4. Flannery, B. A., Roberts, A. J., Cooney, N., Swift, R. M., Anton, R. F., Rohsenow, D. J., "The role of craving in alcohol use, dependence, and treatment", *Alcohol Clin Exp Res*, 25(2):299-308, 2001.
5. Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., Crews, F. T.,

- “Pharmacological treatment of alcohol dependence: a review of the evidence”, *JAMA*, 281(14):1318-25, 1999.
6. Gottschalk, P. C., Jaconsen, L. K., Kosten, T. R., “Current concepts in pharmacotherapy of substance abuse”, *Curr Psychiatry Rep*, 1(2):172-178, 1999.
 7. Himmelsbach, C. K., “The morphine abstinence syndrome, its nature and treatment”, *Annals of Internal Medicine*, 15:829-843, 1941.
 8. Johnson, B. A., Ait-Daoud, N., “Medications to treat alcoholism”, *Alcohol Res Health*, 23(2):99-106, 1999.
 9. Johnson, B. A., Ait-Daoud, N., “Neuropharmacological treatments for alcoholism: scientific basis and clinical findings”, *Psychopharmacology*, 149(4):327-44, 2000.
 10. Littleton, J., “Neurochemical mechanisms underlying alcohol withdrawal”, *Alcohol Health & Research World*, 22(1):13-24, 1998.
 11. Matsumoto, I., Wilcepa, Buckley, T., Dodd, P., Puzkej *et al.*, “Ethanol and gene expression in brain”, *Alcohol Clin Exp Res*, 25(5):82S-86S, 2001.
 12. Nestler, E., “Cellular and molecular mechanisms of addiction”, *Neurobiology of Mental Illness*, Oxford University Press, 1999.
 13. O’Brien, C., “Principles of the pharmacotherapy of substance abuse disorders”, *Neurobiology of Mental Illness*, Oxford University Press, 1999.
 14. O’Malley, S. S., Croop, R. S., Wroblewski, J. M., “Naltrexone in the treatment of alcohol dependence: A combined analysis of two trials”, *Psychiatric Annals*, 25, 11:681-688, 1995.
 15. Rueff, B., “Evaluation of drug treatment of primary alcoholism”, *Rev Prat*, 49(4):400-2, 1999.
 16. Saivin, S., Hulot, T., Chabac, S., Potgieter, A., Durbin, P., Houin, G., “Clinical pharmacokinetics of acamprosate”, *Clin Pharmacokinetics*, 35(5):331-45, 1998.
 17. Sinclair, J. D., “Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism”, *Alcohol Alcohol*, 36(1):2-10, 2001.
 18. Srisurapanont, M., Jarusuraisin, N., “Opioid antagonists for alcohol dependence (Cochrane review)”, *Cochrane Database Syst Rev*, 3:CD001867, 2000.
 19. Suwaki, H., Kalant, H., Higuchi, S., Crabbe, J. C., Ohkuma, S.,

- Katsura, M. *et al.*, "Recent research on alcohol tolerance and dependence", *Alcohol Clin Exp Res*, 25(5):189S, 196S, 2001.
20. Swift, R. M., "Medications and alcohol craving", *Alcohol Research & Health*, 23(3):207-214, 1999.
 21. Tempesta, E., Janiri, L., Bignamini, A., Chabac, S., Potgieter, A., "Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study", *Alcohol Alcohol*, 35(2):202-9, 2000.
 22. Wildemi, Wagstaff, A. J., Acamprosate, "A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification", *Drugs*, 53(6):1038-53, 1997.

CAPÍTULO VI

1. Slemmer, J., "Bupropion is a nicotinic antagonist", *The Journal of Pharmacology and Experimental Therapeutics*, 295(1):321-327, 2000.
2. Siegel, G., "Basic Neurochemistry: molecular, cellular and medical aspects", 6a. ed. en CD-ROM, Lippincott-Raven, 1999.
3. Goodman y Gilman's, "The pharmacological Basis of Therapeutics", 9a. ed. en CD-ROM, McGraw-Hill, 1996.
4. Schneider, R., "Update in addiction medicine", *Ann Intern Med*, 134:387-395, 2001.
5. Van Ree, J. M., Gerrits, M. A., Vanderschuren, L. J., "Opioids, Reward and Addiction: An encounter of Biology, Psychology and Medicine", *Pharmacological Reviews*, 51(2):341-396, 1999.
6. Koob, G., "Drug Addiction", *Neurobiology of Disease*, 7:543-545, 2000.
7. Watkins, S., Koob, G., Markou, A., "Neural mechanisms underlying nicotine addiction: Acute positive reinforcement and withdrawal", *Nicotine & Tobacco Research*, 2:19:37, 2000.
8. Lukas, R. J., Changeux, J. P. *et al.*, "International union of pharmacology, xx. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits", *Pharmacological Reviews*, 51(2):397-401, 1999.
9. Barnard, E. A., Olsen, P., Sieghart, H. M. *et al.*, "International union of pharmacology. xv. Subtypes of (-aminobutyric acidA receptors:

- Classification on the basis of subunit structure and receptor function”, *Pharmacological Reviews*, 50(2):291-313, 1998.
10. Littleton, J., “Neurochemical mechanisms underlying alcohol withdrawal”, *Alcohol Health & Research World*, 22(1):13-24, 1998.
 11. Mihailescu, S., Drucker-Colin, R., “Nicotine and brain disorders”, *Acta Pharmacol Sin*, 21(2):97-104, 2000.
 12. Levin, E. D., Rezvan, A. H., “Development of nicotinic drug therapy for cognitive disorders”, *Eur J Pharmacol*, 393(1-3):141-146, 2000.
 13. Glassman, A. H., Stetner, F., Walsh, B. T., Raizman, P. S., Fleiss, J. L., Cooper, T. B. y Covey, L. S., “Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial”, *JAMA*, 259:2863-2866, 1998.
 14. Swift, R. M., “Medications and alcohol craving”, *Alcohol Research & Health*, 23(3):207-214, 1999.
 15. Sampablo, L., Lores, F., Cool, F., Rebas, P., “Asociación de bupropion y parches de nicotina como terapia para dejar de fumar. Archivos de bronconeumología”, 36(7):377-380, 2000.
 16. Shine, B., “Nicotine vaccine moves toward clinical trial”, *NIDA notes*, 15(5):1, 2000.
 17. Carrera, M. R., Ashley, J. A., Zhou, B., Wirsching, P., Koob, G. F., Janda, K. D., “Cocaine vaccines: antibody protection against relapse in a rat model”, *Proc Natl Acad Sci*, 97(11):6202-6, 2000.
 18. Caulfield, M. P., Birdsall Nigel, J. M., “International union of pharmacology. xvii. Classification of muscarinic acetylcholine receptors”, *Pharmacological reviews*, 50(2):279-290, 1998, 327, 2000.

CAPÍTULO VII

1. Alterman, A. I., Droba, M., Antelo, R. E., Cornish, J. W., Sweeney, K. K., Parikh, G. A., O’Brien, C. P., “Amantadine may facilitate detoxification of cocaine addicts”, *Drug Alcohol Depend*, 31:19-29, 1992.
2. Billman, G. E., “Cocaine: a review of its toxic actions on cardiac function”, *Crit Rev Toxicol*, 25(2):113-132, 1995.
3. Campbell, U. C., Lac, S. T., Carroll, M, E., “Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats”, *Psychopharmacology*, 143(2):209-14, 1999.

4. Carrera, M. R., Ashley, J. A., Zhou, B., Wirsching, P., Koob, G. F., Janda, K. D., "Cocaine vaccines: antibody protection against relapse in a rat model", *Proc Natl Acad Sci*, 23;97(11):6202-6, 2000.
5. Dackis, C. A., Gold, M. S., "New concepts in cocaine addiction: the dopamine depletion hypothesis", *Neurosci Biobehav Rev*, 9(3): 469-77, 1985.
6. Dackis, C. A., Gold, M. S., "Pharmacological approaches to cocaine addiction", *J Subst Abuse Treat*, 2(3):139-45, 1985.
7. Everitt, B. J., Parkinson, J. A., Olmstead, M. C., Arroyo, M., Robledo, P., Robbins, T. W., "Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems", *Ann NY Acad Sci*, 877:412-38, 1999.
8. Fowler, J. S., Volkow, N. D., Nalison, R., Gatley, S. J., "Neuroimaging studies of substance abuse disorders", *Neurobiology of mental illness*, Oxford University Press, 1999.
9. Fox, B. S., Kantak, K. M., Edwards, M. A., Black, K. M., Bollinger, B. K., Botka, A. J. *et al.*, "Efficacy of a therapeutic cocaine vaccine in rodent models", *Nat Med*, 2(10):1129-32, 1996.
10. Fox, B. S., "Development of a therapeutic vaccine for the treatment of cocaine addiction", *Drug Alcohol Depend*, 15:48(3):153-158, 1997.
11. Froimowitz, M., Wu, K. M., Moussa, A., Haidar, R. M., Jurayj, J., George, C., Gardner, E. L., "Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse", *J Med Chem*, 43(26): 4981-92, 2000.
12. Gatley, S. J., Volkow, N. D., Gifford, A. N., Ding, Y. S., Logan, J., Wang, G. J., "Model for estimating dopamine transporter occupancy and subsequent increase in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine", *Biochem Pharmacol*, 53(1):43-52, 1997.
13. Hedetoft, C., Christensen, H. R., "Amphetamine, ecstasy and cocaine. Clinical aspects of acute poisoning", *Ugeskr Laeger*, 161(50):6907-11, 1999.
14. Herridge, P., Gold, M. S., "Pharmacological adjuncts in the treatment of opioid and cocaine addicts", *J Psychoactive Drugs*, 20(3):233-42, 1988.
15. Howell, L. L., Wilcox, K. M., "The dopamine transporter and cocaine

- medication development: drug self-administration in nonhuman primates”, *J Pharmacol Exp Ther*, 298(1):1-6, 2001.
16. Hubner, C. B., Koob, G. F., “Bromocriptine produces decreases in cocaine self-administration in the rat”, *Neuropsychopharmacology*, 3(2):101-8, 1990.
 17. Hyman, S. E., “Substance abuse disorders”, *Neurobiology of mental illness*, Oxford University Press, 1999.
 18. Karler, R., Calder, L. D., Thai, L. H., Bedingfield, J. B., “A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine”, *Brain Res*, 658(1-2):8-14, 1994.
 19. Koob, G. F., Nestler, E. J., “The neurobiology of drug addiction”, *J Neuropsychiatry Clin Neurosci*, 9(3):482-97, 1997.
 20. Malison, R., Best, S., Zoghbi, S., Zea-Ponce, Y., Baldwin, R., Charney, D. *et al.*, “SPECT imaging of dopamine transporters during sustained cocaine abstinence with [123I] β -CIT”, *J Nucl Med*, 37:44, 1996.
 21. Nestler, E. J., “Cellular and molecular mechanisms of addiction”, *Neurobiology of mental illness*, Oxford University Press, 1999.
 22. O’Brien, C. P., “Principles of the pharmacotherapy of substance abuse disorders”, *Neurobiology of mental illness*, Oxford University Press, 1999.
 23. Pilla, M., Perachon, S., Sautel, F., Garrido, F., Mann, A., Wermuth, C. G., Schwartz, J. C., Everitt, B. J., Sokoloff, P., “Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist”, *Nature*, 400(6742):317-319, 1999.
 24. Roberts, D. C., Brebner, K., “GABA modulation of cocaine self-administration”, *Ann NY Acad Sci*, 909:145-58, 2000.
 25. Rocha, B. A., Fumagalli, F., Gainetdinov, R. R., Jones, S. R., Ator, R., Giros, B., Miller, G. W., Caron, M. G., “Cocaine self-administration in dopamine-transporter knockout mice”, *Nat Neurosci*, 1(2):132-7, 1998.
 26. Rump, A. F., Theisohn, M., Klaus, W., “The pathophysiology of cocaine cardiotoxicity”, *Forensic Sci Int*, 71(2):103-15, 1995.
 27. Schabacker, D. S., Kirschbaum, K. S., Segre, M., “Exploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta antibodies”, *Immunology*, 100(1):48-56, 2000.
 28. Shoji, S., Simms, D., Wesley, C., Gallagher, M., “Chronic cocaine

- enhances gamma aminobutyric acid and glutamate release by altering presynaptic and not postsynaptic gamma aminobutyric acid B receptors within the rat dorsolateral septal nucleus”, *J Pharmacol Exp Ther*, 280(1):129-137, 1997.
29. Soyka, M., De Vry, J., “Flupenthixol as a potential pharmacotreatment of alcohol and cocaine abuse/dependence”, *Eur Neuropsychopharmacol*, 10(5):325-32, 2000.
 30. Stein, E. A., “fMRI: a new tool for the in vivo localization of drug actions in the brain”, *J Anal Toxicol*, 25(5):419-24, 2001.
 31. Tella, S. R., Goldberg, S. R., “Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine”, *Pharmacol Biochem Behav*, 59(2):305-12, 1998.
 32. Tella, S. R., “Possible novel pharmacodynamic action of cocaine: cardiovascular and behavioral evidence”, *Pharmacol Biochem Behav*, 54(2):343-54, 1996.

CAPÍTULO VIII

1. Montoya, A. G., Sorrentino, R., Lukas, S. E., Price, B. H., “Long term Neuropsychiatric Consequences of Ecstasy (MDMA): A Critical Review”, Department of Neurology McLean Hospital and Department of Psychiatry, Massachusetts General Hospital (*Trabajo aceptado para publicación*).
2. Obrockiii, J., Buchert, R., Vaterlein, O., “Ecstasy long-term effects on the human nervous system revealed by positron emission tomography”, *Br. J. Psychiatry*, 175:186-188, 1999.
3. Gerra, G., Zaimovic, A., Ferrin, M., Zambelli, U., Timpano, M., “Long lasting effects of 3,4- methylendioxyamphetamine (MDMA or “Ecstasy”) on serotonin function in humans”, *Biol Psychiatry*, 47:127-136, 2000.